Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment
Aquestive Therapeutics, a pharmaceutical company specializing in advancing medicines to improve patients' lives, has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for their product Libervant™ (diazepam) Buccal Film. The NDA is specifically for the treatment of seizure clusters in children between the ages of two and five. While Aquestive had previously received tentative approval for Libervant for patients 12 years and older, they are currently facing an orphan drug block until January 2027.
Alongside the NDA submission, Aquestive has also announced the appointment of Dr. Carl N. Kraus as their new Chief Medical Officer. Dr. Kraus brings with him over two decades of experience in drug development and a strong medical background.